Acellular pertussis vaccines and the role of pertactin and fimbriae

References

• Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev.18(2), 326–382 (2005).
   PubMed Web of Science ®Google Scholar
• Bassinet L, Gueirard P, Maitre B, Housset B, Gounon P, Guiso N. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect. Immun.68(4), 1934–1941 (2000).
   PubMed Web of Science ®Google Scholar
• Carbonetti NH, Artamonova GV, Andreasen C, Bushar N. Pertussis toxin and adenylate cyclase toxin provide a one–two punch for establishment of Bordetella pertussis infection of the respiratory tract. Infect. Immun.73(5), 2698–2703 (2005).
   PubMedGoogle Scholar
• Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine16(20), 1901–1906 (1998).
   PubMed Web of Science ®Google Scholar
• Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine16(20), 1907–1916 (1998).
   PubMed Web of Science ®Google Scholar
• Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine21(25–26), 3542–3549 (2003).
   PubMed Web of Science ®Google Scholar
• Guiso N, Capiau C, Carletti G, Poolman J, Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine17(19), 2366–2376 (1999).
   PubMed Web of Science ®Google Scholar
• Hellwig SMM, Rodriguez ME, Berbers GAM, van de Winkel JGJ, Mooi FR. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J. Infect. Dis.188(5), 738–742 (2003).
   PubMed Web of Science ®Google Scholar
• Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs65(10), 1367–1389 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards KM, Decker MD. Pertussis vaccine. In: Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, PA, USA, 471–528 (2004).
   Google Scholar
• Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr. Infect. Dis. J.16(Suppl. 4), S90–S96 (1997).
   Google Scholar
• Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine21(17–18), 2003–2014 (2003).
   PubMed Web of Science ®Google Scholar
• Olin P. The best acellular pertussis vaccines are multicomponent (commentary). Pediatr. Infect. Dis. J.16(5), 517–519 (1997).
   Google Scholar
• Meade BD, Lynn F, Reed GF et al. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines. Pediatrics96(3 Pt 2), 595–600 (1995).
   PubMed Web of Science ®Google Scholar
• Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med.334(6), 341–348 (1996).
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med.334(6), 349–355 (1996).
   PubMed Web of Science ®Google Scholar
• Blackwelder WC, Storsaeter J, Olin P, Hallander HO. Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am. J. Dis. Child145(11), 1285–1289 (1991).
   PubMedGoogle Scholar
• Olin P, Storsaeter J. Vaccine efficacy. In: A Clinical Trial of Acellular Pertussis Vaccines in Sweden (Technical Report).National Bacteriological Laboratory, Stockholm, Sweden, 1–28 (1988).
   Google Scholar
• Trollfors B, Taranger J, Lagergård T et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med.333(16), 1045–1050 (1995).
   PubMed Web of Science ®Google Scholar
• Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N. Engl. J. Med.334(6), 391–392 (1996).
   PubMed Web of Science ®Google Scholar
• Olin B, Rasmussen F, Gottfarb P. Schedules and protection, simultaneous vaccination and safety: experiences from recent controlled trials. Int. J. Infect. Dis.1(3), 143–147 (1997).
   Google Scholar
• Simondon F, Preziosi MP, Yam A et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine15(15), 1606–1612 (1997).
   PubMed Web of Science ®Google Scholar
• Hoppenbrouwers K, Kanra G, Roelants M et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine17(7–8), 875–886 (1999).
   PubMedGoogle Scholar
• Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet350(9091), 1569–1577 (1997).
   PubMed Web of Science ®Google Scholar
• Pertussis. In: Immunisation Against Infectious Disease – The Green Book. Salisbury D, Ramsay M, Noakes K (Eds). Department of Health, UK, 277–293 (2006).
   Google Scholar
• Poland GA. Still more questions on pertussis vaccines. Lancet350(9091), 1564–1565 (1997).
   PubMedGoogle Scholar
• Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlson R-M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol.43(6), 2856–2865 (2005).
   Google Scholar
• Stefanelli P, De Marzi L, Robino L et al. Characterization of Bordetella pertussis strains of recent isolation. New Microbiol.22(3), 187–194 (1999).
   PubMedGoogle Scholar
• van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E. Bordetella pertussis surveillance in England and Wales: 1995–7. Epidemiol. Infect.123(3), 403–411 (1999).
   Google Scholar
• Englund JA, Glezen WP, Barreto L. Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J. Infect. Dis.166(6), 1436–1441 (1992).
   PubMed Web of Science ®Google Scholar
• Tiru M, Askelöf P, Granström M, Hallander H. Bordetella pertussis serotype of clinical isolates in Sweden during 1970–1995 and influence of vaccine efficacy studies. Dev. Biol. Stand.89, 239–245 (1997).
   Google Scholar
• Preston NW, Carter EJ. Serotype specificity of vaccine-induced immunity to pertussis. Commun. Dis. Rep. CDR Rev.2(13), R155–R156 (1992).
   PubMedGoogle Scholar
• Stehr K, Cherry JD, Heininger U et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics101(1 Pt 1), 1–11 (1998).
   PubMed Web of Science ®Google Scholar
• Hoppe JE, Preston NW. Whooping cough in West Germany. Lancet326(8458), 776 (1985).
   Google Scholar
• Enders G, Rapp I, Biber M, Preston NW, Carter EJ. Whooping cough in Stuttgart. Lancet331(8594), 1113 (1988).
   Google Scholar
• Ramakrishnan S, Newland P, Xing DKL, Heininger U, Cherry JD, Corbel MJ. Serotypes of Bordetella pertussis isolates from German children participating in a pertussis vaccine efficacy trial and from non-study participants living in the same geographic area. 7th International Symposium on Pertussis: Genome, Pathogenesis, and Immunity.Cambridge, UK, 18–22 September, 2002.
   Google Scholar
• Robinson A, Gorringe AR, Funnell SGP, Fernandez M. Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine7(4), 321–324 (1989).
   PubMed Web of Science ®Google Scholar
• Caro V, Elomaa A, Brun D, Mertsola J, He Q, Guiso N. Bordetella pertussis, Finland and France. Emerg. Infect. Dis.12(6), 987–989 (2006).
   PubMed Web of Science ®Google Scholar
• Olin P, Gustafsson L, Barreto L et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine21(17–18), 2015–2021 (2003).
   PubMed Web of Science ®Google Scholar
• Denoël P, Poolman J, Carletti G, Veitch K. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection. Vaccine20(19–20), 2551–2555 (2002).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Barreto L, Eastwood BJ, Medd L, Guasparini R, Mills E. Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine15(3), 295–300 (1997).
   PubMed Web of Science ®Google Scholar
• Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin. Infect. Dis.28(5), 995–1001 (1999).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, De Serres G, MacDonald D et al. The changing age and seasonal profile of pertussis in Canada. J. Infect. Dis.185(10), 1448–1453 (2002).
   PubMed Web of Science ®Google Scholar
• Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr. Infect. Dis. J.22(1), 22–27 (2003).
   PubMed Web of Science ®Google Scholar
• Van Amersfoorth SCM, Schouls LM, van der Heide HGJ et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J. Clin. Microbiol.43(6), 2837–2843 (2005).
   PubMed Web of Science ®Google Scholar
• Elomaa A, Advani A, Donnelly D et al. Strain variation among Bordetella pertussis isolates in Finland, where the whole-cell pertussis vaccine has been used for 50 years. J. Clin. Microbiol.43(8), 3681–3687 (2005).
   PubMed Web of Science ®Google Scholar
• Tsang RSW, Lau AKH, Sill ML et al. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J. Clin. Microbiol.42(11), 5364–5367 (2004).
   PubMed Web of Science ®Google Scholar
• Kourova N, Caro V, Weber C et al. Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J. Clin. Microbiol.41(8), 3706–3711 (2003).
   PubMedGoogle Scholar
• Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL. Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol. Infect.132(2), 185–193 (2004).
   PubMed Web of Science ®Google Scholar
• Kerr JR, Matthews RC. Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur. J. Clin. Microbiol. Infect. Dis.19(2), 77–88 (2000).
   PubMed Web of Science ®Google Scholar
• van Loo IHM, Heuvelman KJ, King AJ, Mooi FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J. Clin. Microbiol.40(6), 1994–2001 (2002).
   PubMed Web of Science ®Google Scholar
• Mooi FR, van Oirschot H, Heuvelman K, van der Heide HGJ, Gaastra W, Willems RJL. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun.66(2), 670–675 (1998).
   PubMed Web of Science ®Google Scholar
• Mooi FR, Hallander H, Wirsing von König CH, Hoet B, Guiso N. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur. J. Clin. Microbiol. Infect. Dis.19(3), 174–181 (2000).
   PubMed Web of Science ®Google Scholar
• Packard ER, Parton R, Coote JG, Fry NK. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol.53(5), 355–365 (2004).
   PubMed Web of Science ®Google Scholar
• Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun.69(9), 5520–5528 (2001).
   PubMed Web of Science ®Google Scholar
• Godfroid F, Denoël P, Poolman J. Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expert. Rev.Vaccines4(5), 757–778 (2005).
   PubMed Web of Science ®Google Scholar
• Caro V, Njamkepo E, van Amersfoorth SCM et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microb. Infect.7(7–8), 976–982 (2005).
   PubMed Web of Science ®Google Scholar
• Byrne S, Slack AT. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999–2003. BMC Infect. Dis.6(1), 53 (2006).
   PubMed Web of Science ®Google Scholar
• de Melker HE, Schellekens JFP, Neppelenbroek SE, Mooi FR, Rümke HC, Conyn-van Spaendonck MAE. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg. Infect. Dis.6(4), 348–357 (2000).
   PubMed Web of Science ®Google Scholar
• Hausman SZ, Burns DL. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect. Immun.68(6), 3763–3767 (2000).
   PubMed Web of Science ®Google Scholar
• Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr. Infect. Dis. J.22(11), 956–959 (2003).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pertussis – United States, 1997–2000. Morb. Mortal. Wkly Rep.51(4), 73–76 (2002).
   PubMedGoogle Scholar
• Forsyth KD, Campins-Marti M, Caro J et al. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin. Infect. Dis.39(12), 1802–1809 (2004).
   PubMed Web of Science ®Google Scholar
• Lee GM, Lett S, Schauer S et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin. Infect. Dis.39(11), 1572–1580 (2004).
   PubMed Web of Science ®Google Scholar
• Güris D, Strebel PM, Bardenheier B et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin. Infect. Dis.28(6), 1230–1237 (1999).
   PubMed Web of Science ®Google Scholar
• Salmaso S, Mastrantonio P, Tozzi AE et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics108(5), e81 (2001).
   PubMed Web of Science ®Google Scholar
• Lacombe K, Yam A, Simondon K, Pinchinat S, Simondon F. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine23(5), 623–628 (2004).
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr. Infect. Dis. J.24(5), S58–S61 (2005).
   PubMedGoogle Scholar
• Baughman AL, Bisgard KM, Edwards KM et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin. Diagn. Lab. Immunol.11(6), 1045–1053 (2004).
   PubMedGoogle Scholar
• Pebody RG, Gay NJ, Giammanco A et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol. Infect.133(1), 159–171 (2005).
   PubMed Web of Science ®Google Scholar
• Águas R, Gonçalves G, Gomes MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect. Dis.6(2), 112–117 (2006).
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics118(3), 978–984 (2006).
   PubMed Web of Science ®Google Scholar
• Ward JI, Cherry JD, Chang SJ et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N. Engl. J. Med.353(15), 1555–1563 (2005).
   PubMed Web of Science ®Google Scholar